Drug Classes Archives - Page 5 of 96

Vaccination after COVID improves immunity; ivermectin fails in major trial

Antiparasitics, Blood Plasma, Children, Convalescent Plasma, CoronaVac (Sinovac Biotech), COVID-19 immunity, COVID-19 Studies, Delta Variant (B.1.617.2; India), Hospitalized COVID-19 Patients, Ivermectin, JAMA Pediatrics, Janssen COVID-19 Vaccine (J&J), Lancet Infectious Diseases, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), R&D, Therapeutics, Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

Although people who recover from COVID-19 usually gain some immune defenses against reinfection, they get additional protection from vaccines, especially against severe disease, according to two studies published on March 31 in The Lancet Infectious Diseases. Additionally, two gold-standard trials published in The New England Journal of Medicine on March 30 help settle questions about two controversial therapies touted by many early in the pandemic with decidedly mixed results – failure for the antiparasite drug ivermectin and success for antibody-rich blood plasma from COVID-19 survivors.

April 1, 2022/by Reuters Health

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

Biologics, Biologics License Application (BLA), Clinical Trials, Monoclonal Antibodies, Monoclonal Antibodies, Oncology, R&D, R&D

Y-mAbs Therapeutics Inc. announced that the company completed the resubmission of its Biologics License Application (BLA) for 131I-omburtamab to the U.S. FDA.

April 1, 2022/by GlobeNewswire

Merck’s Acceleron Integration To Take Out 143 Jobs in Cambridge, MA

Anemia, Blockbusters, Blood Vessels, Business, Cambridge, Clinical Trials, Committee for Medicinal Products for Human Use (CHMP), Erythroid maturation agents, First-In-Class, Job Cuts, Keytruda, Massachusetts, Pulmonary Arterial Hypertension, R&D, Royalties, Therapeutics, Transforming Growth Factor-beta (TGFb)

Merck announced that the company will lay off 170 people from Cambridge, Massachusetts-based Acceleron Pharma, which was acquired during November 2021 for about $11.5 billion.

March 30, 2022/by BioSpace

CDC recommends second COVID booster shot for some people

CDC, COVID-19 booster shots, COVID-19 recommendations, COVID-19 shots, COVID-19 Vaccinations, Emergency Use Authorization (EUA), FDA, Immunocompromised, Messenger RNA (mRNA) Vaccines

The U.S. Centers for Disease Control and Prevention (CDC) on March 29 updated its recommendation to allow certain immunocompromised individuals and people over the age of 50 to receive an additional booster dose of COVID-19 vaccines.

March 29, 2022/by Reuters Health

Bayer to Highlight New Cardiovascular and Renal Data at ACC.22, Including Late-Breaking Presentations for KERENDIA as Well as Oral Factor XIa Inhibitor Program

American College of Cardiology, Bayer, Business, Cardiovascular, Clinical Data, Clinical Trials, Factor XIa (FXIa) Inhibitors, First-In-Class, Kidney Disease, Kidneys, Medical Societies, Mineralocorticoid Receptor Antagonists (MRAs), Pharma Companies, R&D, Therapeutics

Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.

March 29, 2022/by Business Wire

Pfizer’s S1P Therapy Scores Second Phase III Win in Ulcerative Colitis

Clinical Trials, Inflammatory Bowel Disease, Pfizer, R&D, S1P Modulators, Topline Data, Ulcerative Colitis

Pfizer announced positive top-line results from the company’s year-long Phase III trial of etrasimod for the treatment of ulcerative colitis (UC). Pfizer plans to pursue regulatory filings for the drug during 2022.

March 29, 2022/by BioSpace

HIV drugs may lower COVID risk; COVID and flu co-infection raises risk of severe illness, death

Clinical Trials, Coronavirus Disease (COVID-19) Pandemic, HIV, Hospitalized COVID-19 Patients, Influenza, Nasal Sprays, Protease inhibitors, R&D, SARS-CoV-2 virus, Small Molecules, The Lancet, Therapeutics

Certain drugs used to treat HIV may have a role in preventing SARS-CoV-2 infections, according to preliminary data that may help explain why people living with the condition have not appeared to be at higher risk for serious COVID-19 despite being generally more vulnerable to infections. Additionally, having COVID-19 and influenza at the same time puts hospitalized adults at much greater risk of critical illness and death compared to having COVID-19 without the flu, researchers reported in The Lancet.

March 28, 2022/by Reuters Health

Novo Nordisk receives FDA approval of higher-dose Ozempic 2 mg providing increased glycemic control for adults with type 2 diabetes

Approvals, Blockbusters, Blood Sugar Levels, Cardiovascular Events, Deaths, FDA/Regulatory, Glucagon-Like Peptide-1 (GLP-1) Analogs, Heart Attacks, Heart Diseases, New Doses, Stroke, Therapeutics, Type 1 Diabetes

The U.S. Food and Drug Administration approved a 2 mg dose of Novo Nordisk’s Ozempic (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.

March 28, 2022/by PR Newswire

Retrospective Study on Real-World Treatment Patterns and Outcomes of Acthar Gel in Patients with Refractory Rheumatoid Arthritis Published in Drugs in Context

Autoimmune Diseases, Drugs in Context, NSAIDs, Peer-Reviewed Analysis, Refractory rheumatoid arthritis (RA), Standard of care drugs, Therapeutics

Global biopharmaceutical company Mallinckrodt plc announced the publication of findings from a retrospective medical records study assessing the real-world utilization and outcomes of Acthar Gel (repository corticotropin injection) in patients with refractory rheumatoid arthritis (RA) that did not adequately respond to standard-of-care therapies.

March 28, 2022/by PR Newswire

Nobel Laureate Helms New Immunotherapy Research Institute at MD Anderson

Appointments, Checkpoint Inhibitors, CTLA-4, Immunotherapies, Innovation, James P. Allison Institute, MD Anderson Cancer Center, Molecules, Nobel Prize in Physiology or Medicine, Oncology, People on the Move, R&D, Research

Checkpoint inhibitor pioneer James P. Allison, who won the 2018 Nobel Prize in Medicine, will helm a new research and innovation hub at The University of Texas MD Anderson Cancer Center that is focused on developing new immunotherapy breakthroughs in oncology.

March 25, 2022/by BioSpace